{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-075709","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.616892+00:00","generated_at":"2026-06-01T00:58:57.667303+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Carisma nominates first in vivo CAR-M candidate under Moderna collab; $2M milestone triggered","bullets":["Development candidate targets Glypican-3 for solid tumors, including hepatocellular carcinoma (HCC).","Nomination triggers a $2M milestone payment to Carisma from Moderna.","Candidate uses Carisma's CAR-M expertise and Moderna's mRNA/LNP platform for in vivo cell therapy.","Moderna leads development and commercialization; four undisclosed oncology targets also nominated.","Pre-clinical data showed successful in vivo creation of CAR-M redirecting myeloid cells against cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-075709","json":"https://secwatch.observer/filing/0001104659-24-075709.json","markdown":"https://secwatch.observer/filing/0001104659-24-075709.md","text":"https://secwatch.observer/filing/0001104659-24-075709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924075709/0001104659-24-075709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924075709/tm2418383d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:58:57.667303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}